Skip to main content

Incyte Corp

corporate_fare Company Profile

Incyte Corp

INCY·NASDAQ·Industrial Applications And Services·CIK 0000879169

Incyte is a global biopharmaceutical company that discovers, develops, and sells its own medicines. The company's global headquarters is in Wilmington, Delaware, where it handles discovery, clinical development, and commercial operations. Incyte also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland, and other offices across Europe, as well as its Japanese headquarters in Tokyo and Canadian headquarters in Montreal. Incyte focuses on three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). In its Hematology segment, Incyte has four approved products and several clinical development programs. The approved products include JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), and NIKTIMVO (axatilimab-csfr). JAKAFI (ruxolitinib) received U.S. Food and Drug Administration (FDA) approval in November 2011 for adults with intermediate or high-risk myelofibrosis (MF); in December 2014 for adults with polycythemia vera (PV) who did not respond well to or tolerate hydroxyurea; in May 2019 for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and in September 2021 for chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. MF and PV are rare blood cancers called myeloproliferative neoplasms (MPNs), and GVHD is an immune response to a stem cell transplant. JAKAFI has orphan drug status from the FDA for MF, PV, and GVHD. Ruxolitinib phosphate also qualifies for the Small Biotech Exception from the Centers for Medicare and Medicaid Services (CMS) under the Inflation Reduction Act. MF is a rare, life-threatening condition and the most serious MPN, occurring as primary MF or secondary MF in patients who previously had PV or essential thrombocythemia (ET).

Incyte Corp (NASDAQ:INCY) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 34 items for INCY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for INCY spans 10-Q, 8-K.

Recent high-impact activity:

  • Povofortay Wins EU Approval as First Once-Daily Oral HS Treatment
  • Incyte Posts $784.8M Q3 Loss on $1.23B Vega IPR&D Charge as Revenue Climbs 14%
  • Incyte Swings to $3.60/Share Loss but Beats on Revenue, Tops Lowered Bar
  • Incyte Lifts 2026 Sales Outlook as Q3 Revenue Climbs 14% to $1.56B
  • Incyte Strikes CMS Deal for Jakafi Pricing, Secures Exemption from Future Mandates

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5.14B
Net Income
$1.29B
Diluted EPS
$6.41
Op. Cash Flow
$1.41B
Gross Profit
$4.77B
Operating Income
$1.51B
Cash & Equivalents
$3.1B
Debt / Equity
0.00×
Net Margin
25.0%
Shares Outstanding
198.46M sh
Source: 10-K · filed 2026-02-10 · accession 0000879169-26-000010

Short Interest & Short Volume

5.58 days to cover

FINRA reported short interest of 10,649,327 shares in INCY as of the October 30, 2026 settlement, a 6.2% increase from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 53.9% of INCY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,649,327 shares as of October 30, 2026
Change vs prior period▲ 6.2%
Days to cover5.58 at avg daily volume of 1,909,051
Daily short volume (FINRA facilities)53.9% of 579,322 shares on November 20, 2026
5-day average short volume61.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$113.91 -0.62% today
52-week range · as of 2026-10-29 $88.2 – $132.6
Market cap
$23.36B
Volume
1.5M (0.9× avg)
3-mo avg 1.7M
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INCY - Latest Insights

INCY
Nov 16, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.53
Real-time Price: $113.91 info
Change: -$3.62 (-3%) info
Market Cap: $23.364B info
INCY
Oct 29, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $113.91 info
Change: -$2.89 (-2%) info
Market Cap: $23.364B info
INCY
Oct 29, 2026, 11:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.20
Real-time Price: $113.91 info
Change: -$1.29 (-1%) info
Market Cap: $23.364B info
INCY
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.76
Real-time Price: $113.91 info
Change: -$3.85 (-3%) info
Market Cap: $23.364B info
INCY
Aug 31, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $123.22
Real-time Price: $113.91 info
Change: -$9.31 (-8%) info
Market Cap: $23.364B info
INCY
Jul 29, 2026, 6:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $119.00
Real-time Price: $113.91 info
Change: -$5.09 (-4%) info
Market Cap: $23.364B info
INCY
Jul 29, 2026, 4:36 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $119.00
Real-time Price: $113.91 info
Change: -$5.09 (-4%) info
Market Cap: $23.364B info
INCY
Jul 28, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $130.00
Real-time Price: $113.91 info
Change: -$16.09 (-12%) info
Market Cap: $23.364B info
INCY
Jul 28, 2026, 8:58 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $119.10
Real-time Price: $113.91 info
Change: -$5.19 (-4%) info
Market Cap: $23.364B info
INCY
Jul 28, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $118.50
Real-time Price: $113.91 info
Change: -$4.59 (-4%) info
Market Cap: $23.364B info
INCY
Jul 06, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $115.62
Real-time Price: $113.91 info
Change: -$1.71 (-1%) info
Market Cap: $23.364B info
INCY
Jul 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $115.62
Real-time Price: $113.91 info
Change: -$1.71 (-1%) info
Market Cap: $23.364B info
INCY
Jul 06, 2026, 8:39 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $116.25
Real-time Price: $113.91 info
Change: -$2.34 (-2%) info
Market Cap: $23.364B info
INCY
Jul 06, 2026, 7:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $117.28
Real-time Price: $113.91 info
Change: -$3.37 (-3%) info
Market Cap: $23.364B info
INCY
Jun 26, 2026, 8:08 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $109.36
Real-time Price: $113.91 info
Change: +$4.55 (+4%) info
Market Cap: $23.364B info
INCY
Jun 22, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $99.73
Real-time Price: $113.91 info
Change: +$14.18 (+14%) info
Market Cap: $23.364B info
INCY
Jun 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $99.73
Real-time Price: $113.91 info
Change: +$14.18 (+14%) info
Market Cap: $23.364B info
INCY
Jun 08, 2026, 9:34 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $102.83
Real-time Price: $113.91 info
Change: +$11.08 (+11%) info
Market Cap: $23.364B info
INCY
Jun 08, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $102.07
Real-time Price: $113.91 info
Change: +$11.84 (+12%) info
Market Cap: $23.364B info
INCY
Jun 08, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $102.07
Real-time Price: $113.91 info
Change: +$11.84 (+12%) info
Market Cap: $23.364B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets